PharmaLedger Announces Sustainability Plan: September 2022 Press Release
PharmaLedger has formally endorsed the sustainability plan of the project’s results: becoming the PharmaLedger Association.
- The 36-month PharmaLedger consortium project has formally endorsed the sustainability plan of the project’s results: becoming the PharmaLedger Association.
- The newly established PharmaLedger Association, based in Basel, Switzerland, is a not-for-profit organisation that will continue the progress made by the project’s use cases and deploy digital healthcare solutions in the future.
- The PharmaLedger project will now implement the approved sustainability plan and actively recruit members to join the PharmaLedger Association between October 2022 to January 2023.
The press release lists key components of PharmaLedger’s post-governance approach:
- The PharmaLedger Association aims “to enable and foster a Digital Trust Ecosystem (DTE) in healthcare through a standardised and trusted open-source platform.”
- The PharmaLedger Association joins the consortium as the 30th member of the PharmaLedger project.
- The consortium has approved the bylaws of the PharmaLedger Association.
- You can read more about the design features and aims of the PharmaLedger Association in the press release.
PharmaLedger’s Chairman European Forum for Good Clinical Practice Ingrid Klingmann (EFGCP), Industry Project Lead Daniel Fritz (Novartis), Project Coordinator Maria Eugenia (Xenia) Beltran (Universidad Politécnica de Madrid) and Head Serialisation & Digital Enabling Michael Ritter (Takeda) also share their thoughts about this major transition of becoming the PharmaLedger Association.
The PharmaLedger project will focus on “Validation and Sustainability” for the remainder of 2022.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.